Dr. Demetri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408
Summary
- Dr. George Demetri is an oncologist in Boston, MA and is affiliated with multiple hospitals affiliated with Harvard Medical School in the area, primarily the Dana-Farber Cancer Institute. He received his medical degree from Stanford University School of Medicine and has been in practice 34 years. He specializes in Sarcomas and Developmental Therapeutics
.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1989
- University of WashingtonResidency, Internal Medicine, 1983 - 1985
- Stanford University School of MedicineClass of 1983
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- FL State Medical License 2022 - Present
- MA State Medical License 1986 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FASCO) American Society of Clinical Oncologists, 2008
- Super Doctor SuperDoctors.com
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Troglitazone in Treating Patients With Liposarcoma Start of enrollment: 1997 Jun 01
- Bexarotene in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1998 Oct 01
- Rosiglitazone in Treating Patients With Liposarcoma Start of enrollment: 1999 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsImproving Collection and Analysis of Overall Survival Data.Lisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, Anup K Amatya, George D Demetri
Clinical Cancer Research. 2024-09-13 - Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.Gregory M Cote, Candace L Haddox, Edwin Choy, Priscilla A Merriam, Emanuele Mazzola
Clinical Cancer Research. 2024-07-01 - 26 citationsAfamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.Sandra P D'Angelo, Dejka M Araujo, Albiruni R Abdul Razak, Mark Agulnik, Steven Attia
Lancet. 2024-04-13
Lectures
- First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
Other
- Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumorsDemetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/adjuvant-and-neoadjuvant-imatinib-for-gastrointestinal-stromal-tumo
UpToDate, Wolters Kluwer Health - 2013-01-15 - Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GISTDemetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/epidemiology-classification-clinical-presentation-prognostic-featur
UpToDate, Wolters Kluwer Health - 2013-02-04 - Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tractDemetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/local-treatment-for-gastrointestinal-stromal-tumors-leiomyomas-and-
UpToDate, Wolters Kluwer Health - 2013-01-16 - Join now to see all
Press Mentions
- 7 Big Questions About Cancer, AnsweredJanuary 29th, 2025
- For New NCI Director, Work Turns Personal: She Is Diagnosed with CancerDecember 14th, 2022
- Cancer Combination Therapy Company IDRx Launches with $122M Series a FundingAugust 2nd, 2022
- Join now to see all
Grant Support
- Targeted Therapy Resistance Mechanisms In Gastrointestinal Stromal Tumor(Gist)National Cancer Institute2007–2011
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: